Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1392-1401

  Jiang, B ^a   Liu, F ^a   Yang, L ^b   Zhang, W ^a   Yuan, H ^a   Wang, J ^a   Huang, G ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Mutant enriched sequencing; Mutation; Non small cell lung cancer; Polymerase chain reaction; Serum; Tissue

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; CANCER TISSUE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTANT ENRICHED POLYMERASE CHAIN REACTION BASED DNA SEQUENCING; MUTATIONAL ANALYSIS; NON ENRICHED SEQUENCING; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 80052240913     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900425     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Dempke WC, Suto T, Reck M: Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67: 257-274.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
4. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
5. Bria E, Milella M, Cuppone F, et al: Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a metaanalysis. Ann Oncol 2011; epub ahead of print.
6. Metro G, Finocchiaro G, Toschi L, et al: Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 2006; 1: 1-13.
7. Ostoros G, Harisi R, Kovacs G, et al: Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme. Anticancer Res 2005; 25: 4759-4762.
8. Wu JY, Wu SG, Yang CH, et al: Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2011; 72: 205-212.
9. Comis RL: The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005; 10: 467-470.
10. Uramoto H, Mitsudomi T: Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007; 96: 857-863.
11. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
12. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923.
13. Liu Y, Xu ML, Zhong HH, et al: EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas. Pathol Oncol Res 2008; 14: 373-379.
14. Dong QG, Han BH, Huang JS, et al: Analysis of EGFR mutations in 176 cases of non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2006; 28: 686-690[in Chinese, English abstract].
15. Yamamoto H, Toyooka S, Mitsudomi T: Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009; 63: 315-321.
16. Sasaki H, Endo K, Takada M, et al: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007; 58: 324-328.
17. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
18. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
19. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
20. Zhang X, Chang A: Somatic mutations of the epidermal growth factor receptor and nonsmall- cell lung cancer. J Med Genet 2007; 44: 166-172.
21. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with nonsmall-cell lung cancer. Clin Cancer Res 2006; 12: 3915-3921.
22. Kimura H, Suminoe M, Kasahara K, et al: Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007; 97: 778-784.
23. Bai H, Mao L, Wang HS, et al: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 2653-2659.
24. Cohen V, Agulnik JS, Jarry J, et al: Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer 2006; 107: 2858-2865.
25. Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12: 43-48.
26. Yung TK, Chan KC, Mok TS, et al: Singlemolecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076-2084.
27. Fan X, Furnari FB, Cavenee WK, et al: Nonisotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Oncol 2001; 18: 1023-1026.
28. Kahn SM, Jiang W, Culbertson TA, et al: Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 1991; 6: 1079-1083.
29. Toyooka S, Tsukuda K, Ouchida M, et al: Detection of codon 61 point mutations of the Kras gene in lung and colorectal cancers by enriched PCR. Oncol Rep 2003; 10: 1455-1459.
30. Fassina A, Gazziero A, Zardo D, et al: Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009; 62: 1096-1102.
31. Sasaki H, Endo K, Takada M, et al: L858R EGFR mutation status correlated with clinicopathological features of Japanese lung cancer. Lung Cancer 2006; 54: 103-108.
32. Sugio K, Uramoto H, Ono K, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94: 896-903.
33. Jiang B, Zhu ZZ, Liu F, et al: Prevalence of mutation in the epidermal growth factor receptor gene in Chinese patients with nonsmall cell lung cancer. Clin Oncol (R Coll Radiol) 2006; 18: 635.
34. Sozzi G, Roz L, Conte D, et al: Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005; 97: 1848-1850.
35. Wang Z, Wu YL, Zhang GC, et al: EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. Onkologie 2008; 31: 174-178.